Table 1 Comparison of baseline and follow-up characteristics of female participants
Baseline median (IQR), n = 84 | Follow-up median (IQR), n = 77 | |
|---|---|---|
Age | 33.5 (30.0–40.0) | 40.1 (35.7–45.4) |
Current CD4 count | 372 (261–471) | 564 (427–774) |
Time on ART (months) | 16.0 (10.0–26.0) | 82.4 (73.8–94.1) |
n (%) | n (%) | |
|---|---|---|
No schooling | 5 (4.8) | |
Primary School | 14 (13.6) | |
Secondary School | 83 (80.6) | |
Tertiary | 1 (1.0) | |
1st line ART | 84 (100) | 65 (84.4) |
2nd line ART | 0 (0) | 12 (15.6) |
Stavudine | 76 (90.5) | 30 (39.0) |
Lamivudine | 84 (100) | 77 (100) |
Zidovudine | 8 (9.5) | 29 (37.7) |
Tenofovir | 0 (0.0) | 18 (23.4) |
Lopinavir | 0 (0.0) | 12 (15.6) |
Efavirenz | 41 (48.8) | 36 (46.8) |
Nevirapine | 43 (51.2) | 29 (37.7) |